The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 administered in combination with FOLFIRI with and without bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).
 
Joleen Marie Hubbard
Consulting or Advisory Role - Bayer (Inst)
Research Funding - Boston Biomedical (Inst); Genentech (Inst); PRISM Pharma (Inst); Senhwa Biosciences (Inst)
 
Bert H. O'Neil
Consulting or Advisory Role - Acceleron Pharma; Amgen; Bayer; Genentech/Roche; Lilly/ImClone; Sanofi
Speakers' Bureau - Amgen
 
Derek J. Jonker
No Relationships to Disclose
 
Thorvardur Ragnar Halfdanarson
Consulting or Advisory Role - Novartis
 
Alexander Starodub
No Relationships to Disclose
 
Axel Grothey
Consulting or Advisory Role - Amgen (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst); Boston Biomedical (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche
 
Laura Borodyansky
No Relationships to Disclose
 
Chiang Li
No Relationships to Disclose